A SINGLE-ARM, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD-19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA (LBCL)

Registry ID

ALLO-501A-201

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

ALLOGENE THERAPEUTICS INC

Start date

2023-06-28

Last update

2022-12-22

Conditions

• RELAPSED AND/OR REFRACTORY B-CELL LYMPHOMA

Related clinical trials

• A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
• AN OPEN-LABEL, PHASE I/II STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ENGLUMAFUSP ALFA (RO7227166, A CD19 TARGETED 4-1BB LIGAND) IN COMBINATION WITH OBINUTUZUMAB AND IN COMBINATION WITH GLOFITAMAB FOLLOWING A PRE-TREATMENT DOSE OF OBINUTUZUMAB ADMINISTERED IN PARTICIPANTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN¿S LYMPHOMA
• RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 3 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EPCORITAMAB PLUS LENALIDOMIDE COMPARED TO RITUXIMAB PLUS GEMCITABINE AND OXALIPLATIN
• EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING LISOCABTAGENE MARALEUCEL THAT IS NONCONFORMING TO COMMERCIAL RELEASE
• A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION TRIAL OF GEN3013 IN PATIENTS WITH RELAPSED, PROGRESSIVE OR REFRACTORY B-CELL LYMPHOMA
• A MULTI-STAGE RANDOMIZED PHASE II STUDY OF NOVEL COMBINATION THERAPY IN THE TREATMENT OF RELAPSED AND REFRACTORY AGGRESSIVE B-CELL LYMPHOMA

View on source registry